Recently, Yingsi Intelligent announced that it had successfully completed a US$110 million Series E financing, which has attracted widespread attention in the field of biomedical technology. As a company focusing on generative artificial intelligence technology, Yingsi Intelligent's financing was jointly led by private equity funds under Huili Group, Pudong Venture Capital, Pudong Venture Capital, Tin Venture Capital and Yixing Guokong. In addition, many new investors have also actively participated in this round of financing and have received continuous support from existing investors.
Yingsi Intelligent said that the funds from this round of financing will be mainly used to promote the company's breakthroughs in innovation in artificial intelligence platforms and drug research and development pipelines. Specifically, the funds will be divided into two major uses: on the one hand, it will be used to improve and enhance the company's proprietary artificial intelligence models and algorithms, while upgrading and expanding its leading automated robot laboratory to realize and optimize the automation of R&D processes and further improve R&D efficiency and accuracy.
On the other hand, InSilicon Intelligence will invest its funds in the clinical validation of core drug candidates, especially drugs used to treat idiopathic pulmonary fibrosis (IPF). At the same time, the company will also accelerate the exploration of other independent research and development and cooperative development drug pipelines, in order to achieve more breakthrough innovations in the field of biomedical research and development.
As a biopharmaceutical technology company powered by generative artificial intelligence, the success of this E-round financing not only injects strong impetus into the company's future development, but also demonstrates the capital market's recognition and confidence in Yingsi Intelligent's innovation capabilities in the biopharmaceutical field. With the injection of funds, Yingsi Intelligent is expected to make more breakthroughs in the fields of artificial intelligence and drug research and development, bringing more innovative therapies to patients around the world.